Coherus BioSciences Inc
NASDAQ:CHRS
Coherus BioSciences Inc
Gross Profit
Coherus BioSciences Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Coherus BioSciences Inc
NASDAQ:CHRS
|
Gross Profit
$125.2m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Coherus BioSciences Inc's Gross Profit?
Gross Profit
125.2m
USD
Based on the financial report for Mar 31, 2024, Coherus BioSciences Inc's Gross Profit amounts to 125.2m USD.
What is Coherus BioSciences Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
29%
Over the last year, the Gross Profit growth was 18%. The average annual Gross Profit growth rates for Coherus BioSciences Inc have been -32% over the past three years , 29% over the past five years .